Harrison is a graduate of the University of Virginia and is presently a doctoral candidate in the Virginia Commonwealth University School of Medicine’s Pharmacology and Toxicology department. His research background includes over 5 years of clinical trial conduct consulting on abuse liability assessment and pharmacovigilance monitoring for industry sponsored trials of opioid and cannabinoid medications. During his time in industry, he contributed to the abuse potential assessment of novel opioid medications and the now approved cannabinoid therapeutic Epidiolex. For the last 3 years he has conducted preclinical research into the behavioral pharmacology of opioids, psychostimulants, and psychedelics in conjunction with several laboratories in the School of Medicine. Harrison’s primary interests include research into the therapeutic use of psychedelic compounds and the pursuant regulatory issues surrounding the use of controlled substances in research and medicine.
The potential neurotoxicity of MDMA led to the development of APBs, a family of entactogens whose effect profiles may position them as attractive candidates for the next generation of entactogenic medicines.